- Trials with a EudraCT protocol (1)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1 result(s) found for: 2021-001198-22.
Displaying page 1 of 1.
EudraCT Number: 2021-001198-22 | Sponsor Protocol Number: ALXN2040-GA-201 | Start Date*: 2021-12-02 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) | |||||||||||||
Medical condition: Geographic Atrophy (AD) secondary to Age-related Macular Degeneration (AMD). | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Trial now transitioned) CZ (Trial now transitioned) SK (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
